Cargando…

Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease

Metabolic-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease worldwide. However, its pathophysiological mechanism is complicated, and currently, it has no FDA-approved pharmacological therapies. In recent years, mesenchymal stem cell (MSC) therapy has attracted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Sitong, Cong, Qingwei, Zhu, Ying, Xu, Qiumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839417/ https://www.ncbi.nlm.nih.gov/pubmed/36644008 http://dx.doi.org/10.1155/2023/3919002

Ejemplares similares

Non‑coding RNAs: Role of miRNAs and lncRNAs in the regulation of autophagy in hepatocellular carcinoma (Review)
por: Wu, Jia, et al.
Publicado: (2023)

Metabolic effects of reduced growth hormone action in fatty liver disease
por: Rufinatscha, Kerstin, et al.
Publicado: (2018)

Characteristics of gut microbiota in patients with metabolic associated fatty liver disease
por: Yang, Chao, et al.
Publicado: (2023)

Metabonomics Research Progress on Liver Diseases
por: Yu, Mengqian, et al.
Publicado: (2017)

Cellular and Molecular Mechanisms of Mesenchymal Stem Cell Actions
por: Christ, Bruno, et al.
Publicado: (2017)

Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023)

Metabolic-associated Fatty Liver Disease
por: Zheng, Ming-Hua
Publicado: (2021)

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
por: Miao, Lei, et al.
Publicado: (2022)

Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
por: Zeng, Minghui, et al.
Publicado: (2023)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease
por: Zhang, Ni, et al.
Publicado: (2023)

Metabolic-associated fatty liver disease and lipoprotein metabolism
por: Heeren, Joerg, et al.
Publicado: (2021)

Mechanism of Action of Icariin in Bone Marrow Mesenchymal Stem Cells
por: Yang, Aofei, et al.
Publicado: (2019)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Update on genetics and epigenetics in metabolic associated fatty liver disease
por: Zhu, Xiaopeng, et al.
Publicado: (2022)

Macrophages in metabolic associated fatty liver disease
por: Alharthi, Jawaher, et al.
Publicado: (2020)

Alcohol and Metabolic-associated Fatty Liver Disease
por: Sun, Fu-Rong, et al.
Publicado: (2021)

The lipidome in nonalcoholic fatty liver disease: actionable targets
por: Pirola, Carlos J., et al.
Publicado: (2021)

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application
por: Xu, Yu, et al.
Publicado: (2020)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
por: Badmus, Olufunto O., et al.
Publicado: (2022)

Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities
por: Okada, Akira, et al.
Publicado: (2022)

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
por: Kang, Seong Hee, et al.
Publicado: (2021)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies
por: Moll, Guido, et al.
Publicado: (2020)

Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice
por: Kang, Kai, et al.
Publicado: (2021)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Association between metabolic syndrome and the development of non-alcoholic fatty liver disease
por: WANG, YI, et al.
Publicado: (2013)

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
por: Pei, Ke, et al.
Publicado: (2020)

An Update in Epigenetics in Metabolic-Associated Fatty Liver Disease
por: Rodríguez-Sanabria, J. Samael, et al.
Publicado: (2022)

Infections at the nexus of metabolic-associated fatty liver disease
por: Boeckmans, Joost, et al.
Publicado: (2021)

Biochemical assessment of metabolic associated fatty liver disease
por: Guerra-Ruiz, Armando R., et al.
Publicado: (2021)

Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease
por: Xiao, Yuji, et al.
Publicado: (2023)

The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms
por: Xu, Bilin, et al.
Publicado: (2017)

Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease
por: Lin, Tong, et al.
Publicado: (2021)

Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

Antioxidant-upregulated mesenchymal stem cells reduce inflammation and improve fatty liver disease in diet-induced obesity
por: Domingues, Cleyton C., et al.
Publicado: (2019)

Lipoprotein metabolism in nonalcoholic fatty liver disease
por: Jiang, Zhenghui Gordon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ss05au01vva7dp9b5m595fdq7c